Literature DB >> 29636111

Anti-CCP antibodies and bone.

Giovanni Orsolini1, Ombretta Viapiana2, Maurizio Rossini2, Giovanni Adami2, Cristian Caimmi2, Angelo Fassio2, Davide Gatti2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29636111      PMCID: PMC5894147          DOI: 10.1186/s13075-018-1566-3

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


× No keyword cloud information.
Dear Editor. We read with great interest the paper of Cheng et al. [1]. They demonstrate for the first time as anti-cyclic citrullinated peptides antibodies (Anti-CCP) are an independent risk factor for fracture and this data is of high clinical relevance in stratifying rheumatoid arthritis (RA) patients. The authors have a wide population and were able to take into consideration a lot of factors involved in bone disease related and unrelated to RA. They did confirm our previous reports of a negative effect of Anti-CCP on BMD [2], and also showed a relation with FRAX 10 year calculated fracture risk. In particular, the BMD difference was observed at femoral neck, site of cortical bone that is the same of periarticular bone were erosions occur [3, 4]. Nevertheless, the Authors failed to find any correlation between Anti-CCP titer and BMD. This last data is in contrast with other previous clinical reports of a titer dependent effect of Anti-CCP on bone [2, 5]. The reasons of these discrepancies are not straightforward. A possible explanation of lack of correlation between Anti-CCP titer and BMD could be the use of BMD as g/cm2 and not as Z-score in the analysis. Z-score has the advantage to evaluate better the bone loss correcting for age and gender. Another possible confounder is the evaluation of glucocorticoids (GCs) as a dichotomous variable. It is not clear how the patients were considered “users” and there were no data on mean dose or duration of use, thus of a cumulative dose. The Authors report also data on anti-osteoporosis medications, but they are unspecified, even if they probably refer to antiresorptive drugs. Moreover, data on vitamin D and calcium, either supplements and serum levels, are completely lacking. Vitamin D and PTH are key determinants of cortical bone (e.g. femoral neck) mass [3], so their inclusion in the analysis would have been of critical importance. We think the paper is of great interest but that some of the variables taken into consideration should be implemented and that a more complex statistical analysis is needed to take the best from its data.
  5 in total

1.  Osteoporosis: an Independent Determinant of Bone Erosions in Rheumatoid Arthritis?

Authors:  Maurizio Rossini; Giovanni Adami; Ombretta Viapiana; Luca Idolazzi; Giovanni Orsolini; Angelo Fassio; Alessandro Giollo; Davide Gatti
Journal:  J Bone Miner Res       Date:  2017-08-01       Impact factor: 6.741

2.  Titer-Dependent Effect of Anti-Citrullinated Protein Antibodies On Systemic Bone Mass in Rheumatoid Arthritis Patients.

Authors:  Giovanni Orsolini; Cristian Caimmi; Ombretta Viapiana; Luca Idolazzi; Elena Fracassi; Davide Gatti; Giovanni Adami; Maurizio Rossini
Journal:  Calcif Tissue Int       Date:  2017-02-28       Impact factor: 4.333

3.  Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis.

Authors:  Maurizio Rossini; Gianfilippo Bagnato; Bruno Frediani; Annamaria Iagnocco; Giovanni LA Montagna; Giovanni Minisola; Maurizio Caminiti; Massimo Varenna; Silvano Adami
Journal:  J Rheumatol       Date:  2011-04-01       Impact factor: 4.666

4.  Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.

Authors:  Serena Bugatti; Laura Bogliolo; Barbara Vitolo; Antonio Manzo; Carlomaurizio Montecucco; Roberto Caporali
Journal:  Arthritis Res Ther       Date:  2016-10-06       Impact factor: 5.156

5.  Anti-CCP-positive patients with RA have a higher 10-year probability of fracture evaluated by FRAX®: a registry study of RA with osteoporosis/fracture.

Authors:  Tien-Tsai Cheng; Shan-Fu Yu; Fu-Mei Su; Yin-Chou Chen; Ben Yu-Jih Su; Wen-Chan Chiu; Chung-Yuan Hsu; Jia-Feng Chen; Chi-Hua Ko; Han-Ming Lai
Journal:  Arthritis Res Ther       Date:  2018-01-30       Impact factor: 5.156

  5 in total
  2 in total

1.  Effect of sarcopenia and poor balance on vertebral spinal osteoporotic fracture in female rheumatoid arthritis.

Authors:  Mei Zhang; Shengqian Xu; Hexiang Zong; Jianxiong Wang; Yiran Chu; Jingyu Cai; Ling Chang
Journal:  Sci Rep       Date:  2022-06-08       Impact factor: 4.996

Review 2.  Osteoporosis in Rheumatic Diseases.

Authors:  Giovanni Adami; Angelo Fassio; Maurizio Rossini; Cristian Caimmi; Alessandro Giollo; Giovanni Orsolini; Ombretta Viapiana; Davide Gatti
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.